Does severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series*

T. Rosenberg, A.D. Fialla, J. Kjeldsen, A.D. Kjeldsen

1 Department of ORL-Head & Neck Surgery, Odense University Hospital, Denmark
2 Department of Clinical Research, University of Southern Denmark
3 Department of Medical Gastroenterology and Hepatology, Odense University Hospital, Denmark

Abstract
Background: Hereditary Haemorrhagic Telangiectasia (HHT) is an autosomal dominant genetic disorder, with a wide variety of clinical manifestations due to the presence of multiple arteriovenous manifestations. Severe bleeding from the gastrointestinal (GI) tract and/or epistaxis presents a significant problem in a subgroup of patients and systemic bevacizumab, an angiogenesis inhibitor, has been suggested to benefit these patients.

Objective: To perform a review of the literature concerning the efficacy of systemic bevacizumab in treatment of bleeding from the nose or GI tract in patients with HHT, including patients from our own HHT-center.

Methods: A literature review was performed using the guideline "Preferred Reporting Items for systematic Reviews and Meta-Analysis statement" (PRISMA).

Results: After careful selection, we finally analysed the results of eight case series and 33 case reports. Among 195 patients 171 (88%) had reduced bleeding after bevacizumab.

Conclusions: Based on the literature review and data from our own case series, systemic bevacizumab is very promising as treatment for HHT patients with severe epistaxis and/or GI-bleeding. However, care should be taken using bevacizumab, a potent angiogenesis inhibitor; long-term side effects have not been studied in this population. A randomized controlled study is warranted to support the results in HHT patients.

Key words: Hereditary haemorrhagic telangiectasia, HHT, bevacizumab, epistaxis, GI-bleeding

Introduction
Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu disease, is an autosomal dominantly inherited disease, with a high age-dependent penetrance, an extremely variable expression and a very heterogeneous phenotypic presentation. It is a rare condition affecting 1 in 5,000-8,000 patients (1). The HHT diagnosis is based on diagnostic criteria established in 2000 (Table 1) (2). Approximately 800 Danes are expected to have HHT. HHT is caused by a mutation in one of three genes: ENG (MIM*131195; HHT1), ACVRL1 (MIM*601284; HHT2) or SMAD4 (MIM*600993JP-HHT: combination of juvenile polyposis and HHT) (3). Clinical manifestations differ widely between HHT patients, even within family members carrying the same disease-causing mutation. The most common symptom is recurrent, spontaneous epistaxis due to telangiectatic lesions in the nasal mucosa. Usually, the disease debuts in childhood and progress with age; with ultimately 95 % of the patients experiencing epistaxis. The severity of epistaxis differs between patients, ranging from nosebleeds occurring occasionally and lasting less than one minute to multiple gushing haemorrhages daily resulting in transfusion dependency (4-6). Gastrointestinal (GI) bleeding
is also a common symptom in HHT caused by telangiectatic lesions, present in 13-30% of HHT patients. Similar to epistaxis, GI bleeding tends to become more prominent with increasing age and in some patients resulting in anaemia and a need for repetitive blood transfusion. In addition, patients may also suffer from symptoms caused by arteriovenous malformations in other organs.

Current treatment of epistaxis ranges from intranasal medical treatment to local treatment in the nasal cavity with laser, nasal packing, and nasal closure in the worst afflicted patients. The main treatment for telangiectatic lesions in the GI tract is thermal probes or local laser treatment. Treatment of anaemia includes oral and intravenous (IV) iron substitution. In patients with severe bleeding blood transfusions are needed.

To reduce bleeding various medical systemic strategies, including oestrogen, octreotide, thalidomide, and tamoxifen have been used, without consistent effect. Recently, a positive effect of systemic bevacizumab regarding severity of bleeding was reported in HHT patients with severe hepatic vascular malformation in a phase 2 trial. Several case series and case reports have shown reduced bleeding in selected patients treated with systemic bevacizumab.

Bevacizumab is an anti-vascular endothelial growth factor (VEGF) monoclonal humanized antibody that prevents the binding of VEGF to the VEGF receptor on endothelial cells and in this way inhibits cellular proliferation and angiogenesis. In HHT the vascular malformations are thought to result from an imbalance in the process of angiogenesis driven by VEGF and increased plasma concentrations and tissue expression of VEGF in HHT patients have been found. Thus it has been suggested that bevacizumab may be a treatment option for the vascular malformations in HHT. Local treatment with nasal spray administered bevacizumab has been studied and no effect of this treatment was documented.

Thus the aim of the present study was to estimate the effect of systemic IV bevacizumab in the treatment of bleeding from the nasal mucosa and/or the GI tract due to telangiectatic lesions in HHT patients by conducting a systematic literature review, and by reviewing our own case series.

Materials and methods
A literature review was performed in accordance with the guideline “Preferred Reporting Items for systematic Reviews and Meta-Analysis statement” (PRISMA). The review protocol has been registered in the PROSPERO International Prospective Register of Systematic Reviews, registration number CRD42018091601.

Systematic literature search
A PICOS (Population, Intervention, Comparison, Outcome, and Systematic literature search) strategy was adopted for the search. The target population consisted of HHT patients suffering from epistaxis and/or GI bleeding. The intervention was systemic IV bevacizumab, and the comparator comprised other treatment modalities prior to IV bevacizumab treatment. The outcome measures were hemoglobin levels and units of transfusion before and after treatment, and adverse events after treatment. The study design was without restrictions as long as original data were available. On January 21, 2018 we searched the electronic bibliographic databases PubMed, Embase, and Cochrane without restrictions on publication date. The search strategy was based on a combination of all available free text and Medical Subject Heading terms for HHT, bevacizumab, and bleeding (complete search strategy can be requested from the authors). The search strategy was developed with help from a scientific librarian, and the electronic search was performed by the first author (TR). The search was repeated on September 12, 2018.

Study selection
Studies identified in the literature search were entered into End-Note version X8 (Thompson Reuters, Carlsbad, CA, USA). Duplicates were removed manually. To assess the eligibility of studies, two authors (ADF and AK) independently screened the titles and the abstracts using predefined criteria for inclusion and exclusion. Finally, the same authors independently evaluated the full text version of all publications selected after the screening process. At each step, discrepancies were solved by discussion and if needed, a third evaluator (JK) acted as arbitrator. In case of any doubt, the article proceeded to the next level.

Language was restricted to English, Swedish, Norwegian, German, or Danish. Studies eligible for inclusion were randomized controlled studies, case series, and case reports.

We supplemented the review of the literature with our unpublished data on 12 patients.

Data item and collection process
Two authors (ADF and AK) performed data extraction, and any discrepancies were resolved through discussion. Data were
Table 2. Description of the 12 patients receiving intravenous bevacizumab at Odense University Hospital from 2013 to 2017.

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Age, years</th>
<th>M/F</th>
<th>HHT type</th>
<th>Epistaxis (y/n) at treatment start</th>
<th>GI-bleeding (y/n) at treatment start</th>
<th>Units of blood 6 months prior to bevacizumab</th>
<th>Units of blood 6 months after induction therapy</th>
<th>Haemoglobin prior to bevacizumab (g/dl)</th>
<th>Haemoglobin 12 weeks after induction therapy (g/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>79</td>
<td>F</td>
<td>HHT1</td>
<td>N</td>
<td>Y</td>
<td>24</td>
<td>N.A.*</td>
<td>4.6 (7.4)</td>
<td>5.4 (8.7)</td>
</tr>
<tr>
<td>2</td>
<td>60</td>
<td>F</td>
<td>HHT1</td>
<td>N</td>
<td>Y</td>
<td>8</td>
<td>9</td>
<td>6.0 (9.7)</td>
<td>5.8 (9.4)</td>
</tr>
<tr>
<td>3</td>
<td>65</td>
<td>M</td>
<td>HHT2</td>
<td>N</td>
<td>Y</td>
<td>7</td>
<td>0</td>
<td>7.0 (11.3)</td>
<td>10.1 (16.3)</td>
</tr>
<tr>
<td>4</td>
<td>69</td>
<td>M</td>
<td>HHT1</td>
<td>Y</td>
<td>N</td>
<td>6</td>
<td>0</td>
<td>5.2 (8.4)</td>
<td>7.7 (12.4)</td>
</tr>
<tr>
<td>5</td>
<td>78</td>
<td>F</td>
<td>HHT2</td>
<td>Y</td>
<td>Y</td>
<td>12</td>
<td>0</td>
<td>5.3 (8.5)</td>
<td>7.9 (12.7)</td>
</tr>
<tr>
<td>6</td>
<td>70</td>
<td>M</td>
<td>HHT1</td>
<td>Y</td>
<td>N</td>
<td>6</td>
<td>2</td>
<td>5.8 (9.4)</td>
<td>7.4 (11.9)</td>
</tr>
<tr>
<td>7</td>
<td>68</td>
<td>F</td>
<td>HHT2</td>
<td>Y</td>
<td>N</td>
<td>0</td>
<td>0</td>
<td>7.9 (12.7)</td>
<td>8.4 (13.5)</td>
</tr>
<tr>
<td>8</td>
<td>60</td>
<td>F</td>
<td>HHT2</td>
<td>N</td>
<td>Y</td>
<td>20</td>
<td>0</td>
<td>5.0 (8.1)</td>
<td>8.2 (13.2)</td>
</tr>
<tr>
<td>9</td>
<td>68</td>
<td>F</td>
<td>HHT2</td>
<td>Y</td>
<td>N</td>
<td>32</td>
<td>4</td>
<td>5.9 (9.5)</td>
<td>7.9 (12.7)</td>
</tr>
<tr>
<td>10</td>
<td>65</td>
<td>F</td>
<td>HHT1</td>
<td>Y</td>
<td>N</td>
<td>0</td>
<td>0</td>
<td>6.7 (10.8)</td>
<td>7.4 (11.9)</td>
</tr>
<tr>
<td>11</td>
<td>67</td>
<td>M</td>
<td>HHT2</td>
<td>Y</td>
<td>N</td>
<td>11</td>
<td>0</td>
<td>5.9 (9.5)</td>
<td>8.8 (14.2)</td>
</tr>
<tr>
<td>12</td>
<td>63</td>
<td>F</td>
<td>HHT2</td>
<td>Y</td>
<td>Y</td>
<td>0</td>
<td>0</td>
<td>5.0 (8.1)</td>
<td>7.1 (11.4)</td>
</tr>
</tbody>
</table>

Median 68 years

8 units 0 units

5.9 mmol/l (9.5 g/dl) 7.9 mmol/l (12.7 g/dl)

*) Patient died in the follow-up period due to severe HHT manifestations.

extracted with regard to the number of patients, age at bevacizumab treatment, HHT type, presence of epistaxis, GI bleeding, pulmonary arteriovenous malformations (PAVMs), hepatic AVMs (HAVMs), indication for treatment, dosage of bevacizumab, number of treatments and interval between treatments, severity of bleeding, transfusion need, hemoglobin level, and adverse events.

Patient subgroups not relevant to our study were excluded from the study population before statistical analysis.

Quality assessment of individual studies
Quality assessment of individual studies was based on the recent published guidelines “Tool for evaluating the methodological quality of case reports and case series” (24). Each study was evaluated according to four domains (selection, ascertainment, causality, and reporting) by two independent authors (AK and JK), leading to an overall assessment for each study. The evaluations were based on the research question in the present review.

Synthesis of results
A descriptive synthesis was conducted, summarizing occurrence of epistaxis and/or GI bleeding before treatment, treatment indication, treatment efficacy, and adverse events. Data from case series and case reports were analyzed separately.

Own case series
All HHT patients treated with bevacizumab in the period 2013...
Intravenous bevacizumab for HHT patients

Results
Study selection and characteristics
The literature search resulted in 265 records. The study selection process is illustrated in Figure 1. Forty-nine publications were analyzed as full text and five as abstracts, and their quality was assessed according to newly published recommendations [24]. Thirty-four of these publications met all eligibility criteria and were included in the review, as were five abstracts with sufficient original data and our own unpublished dataset. The repeated search in September 2018 resulted in one extra case report [25] and one extra case series [26]. Characteristics of the eight case series [17,23,26-31] and the 33 case reports [25,32-62] included in the present study are summarized in Table 3 and Table 4, respectively, including study type, number of patients, gender,
Table 4. Results of bevacizumab treatment in 33 case reports.

<table>
<thead>
<tr>
<th>Study</th>
<th>Sex/Age</th>
<th>Symptoms</th>
<th>Treatment indication</th>
<th>Treatment protocol</th>
<th>Efficacy of treatment</th>
<th>Adverse effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amann et al. 2015</td>
<td>F 66</td>
<td>Epistaxis, PAVM, HAVM</td>
<td>Epistaxis</td>
<td>5</td>
<td>6</td>
<td>2 DB Increased HR; Died during follow-up after cerebral abscess</td>
</tr>
<tr>
<td>Bennesser et al. 2015</td>
<td>M 66</td>
<td>Epistaxis, GI bleeding, PAVM</td>
<td>Epistaxis</td>
<td>5</td>
<td>6</td>
<td>2 Yes (not specified)</td>
</tr>
<tr>
<td>Bertoli et al. 2017</td>
<td>M 47</td>
<td>Epistaxis, GI bleeding</td>
<td>Epistaxis + melena</td>
<td>2.5</td>
<td>12</td>
<td>2 DB, DT, IH</td>
</tr>
<tr>
<td>Bernardes et al 2018</td>
<td>F 62</td>
<td>GI Bleeding</td>
<td>melena</td>
<td>7.5 (5)</td>
<td>&gt; 6</td>
<td>3 DB, DT, IH</td>
</tr>
<tr>
<td>Bose et al. 2009</td>
<td>M 42</td>
<td>Epistaxis, PAVM</td>
<td>Epistaxis + hemoptysis</td>
<td>10 + 5</td>
<td>2 + 2</td>
<td>2 DB, IH</td>
</tr>
<tr>
<td>Bourgue et al. 2012</td>
<td>M 45</td>
<td>Epistaxis</td>
<td>Epistaxis</td>
<td>5</td>
<td>4 years</td>
<td>4 None Colonic ischemia</td>
</tr>
<tr>
<td>Brinkerhoff et al. 2011</td>
<td>M 62</td>
<td>Epistaxis</td>
<td>Epistaxis</td>
<td>5</td>
<td>4</td>
<td>2 DB, DT, IH Treatment was repeated</td>
</tr>
<tr>
<td>Brinkerhoff et al. 2012</td>
<td>F 55</td>
<td>Epistaxis</td>
<td>Epistaxis</td>
<td>10 + 5</td>
<td>2 + 2</td>
<td>2 DB, IH Treatment was repeated once</td>
</tr>
<tr>
<td>Busiek et al. 2010</td>
<td>M 77</td>
<td>Epistaxis, GI bleeding</td>
<td>Epistaxis + melena</td>
<td>5</td>
<td>6</td>
<td>2 DB, DT</td>
</tr>
<tr>
<td>Castillo et al. 2016</td>
<td>M 67</td>
<td>Epistaxis, GI bleeding</td>
<td>Epistaxis + melena</td>
<td>5</td>
<td>6</td>
<td>2 DB, DT, IH</td>
</tr>
<tr>
<td>Epperla et al. 2015</td>
<td>F 57</td>
<td>Epistaxis, GI bleeding, PAVM</td>
<td>Epistaxis + melena</td>
<td>10</td>
<td>3</td>
<td>2 DB, DT, IH</td>
</tr>
<tr>
<td>Cruikshank et al. 2011</td>
<td>M 71</td>
<td>Epistaxis, GI bleeding</td>
<td>Epistaxis + melena</td>
<td>5</td>
<td>6</td>
<td>2 DB, DT, IH Poor sleep</td>
</tr>
<tr>
<td>Fleagle et al. 2012</td>
<td>F 52</td>
<td>Epistaxis, GI bleeding</td>
<td>Epistaxis + melena</td>
<td>5</td>
<td>4</td>
<td>2 DB, DT, IH Staphylococcus aureus sepsis</td>
</tr>
<tr>
<td>Flieger et al. 2006</td>
<td>M 73</td>
<td>GI bleeding, HAVM</td>
<td>Melena + mesothelioma</td>
<td>5</td>
<td>7</td>
<td>2 DB, DT, IH</td>
</tr>
<tr>
<td>Fodstad et al. 2010</td>
<td>M 44</td>
<td>Epistaxis, GI bleeding, PAVM, HAVM</td>
<td>Epistaxis + melena</td>
<td>5</td>
<td>10</td>
<td>2-3 DB, DT, IH</td>
</tr>
<tr>
<td>Follner et al. 2012</td>
<td>M 82</td>
<td>GI bleeding</td>
<td>Melena</td>
<td>5</td>
<td>3</td>
<td>2 DB, DT, IH</td>
</tr>
<tr>
<td>Follner et al. 2012</td>
<td>F 55</td>
<td>Epistaxis, GI bleeding</td>
<td>Epistaxis + melena</td>
<td>5</td>
<td>3</td>
<td>2 None</td>
</tr>
<tr>
<td>Huemer et al. 2016</td>
<td>M 57</td>
<td>Epistaxis, PAVM</td>
<td>Epistaxis</td>
<td>1</td>
<td>16</td>
<td>2 DB, DT, IH Treatment repeated after 300 days</td>
</tr>
<tr>
<td>Kochanowski et al. 2015</td>
<td>F 56</td>
<td>Epistaxis, GI bleeding</td>
<td>Melena</td>
<td>3.1</td>
<td>6</td>
<td>3 DB, DT, IH</td>
</tr>
<tr>
<td>Lazarki et al. 2011</td>
<td>F 71</td>
<td>Epistaxis, GI bleeding, HAVM</td>
<td>Epistaxis + melena</td>
<td>5</td>
<td>12</td>
<td>2 DB, DT, IH Treatment was repeated</td>
</tr>
<tr>
<td>Lupu et al. 2013</td>
<td>F 85</td>
<td>GI bleeding, HAVM</td>
<td>Melena</td>
<td>3</td>
<td>5</td>
<td>3 DB, DT, IH</td>
</tr>
<tr>
<td>Marz et al. 2011</td>
<td>?? 56</td>
<td>Epistaxis, GI bleeding</td>
<td>Melena</td>
<td>5</td>
<td>NA</td>
<td>2 DB, DT, IH</td>
</tr>
<tr>
<td>Marzolo et al. 2014</td>
<td>F 71</td>
<td>Epistaxis, HAVM</td>
<td>Epistaxis + cardiac failure</td>
<td>5</td>
<td>6</td>
<td>3 DB, DT</td>
</tr>
<tr>
<td>Morales et al. 2012</td>
<td>F 59</td>
<td>Epistaxis, HAVM</td>
<td>Epistaxis + liver deterioration</td>
<td>5</td>
<td>6</td>
<td>2 DB</td>
</tr>
<tr>
<td>Oosting et al. 2009</td>
<td>M 55</td>
<td>Epistaxis, pancreatitis</td>
<td>Epistaxis + avm of pancreas</td>
<td>5 + 7.5</td>
<td>10 + 16</td>
<td>2 DB,</td>
</tr>
<tr>
<td>Ospina et al. 2017</td>
<td>F 5</td>
<td>Epistaxis, PAVM</td>
<td>Epistaxis + PAVM</td>
<td>5</td>
<td>6</td>
<td>2 DB</td>
</tr>
</tbody>
</table>
Intravenous bevacizumab for HHT patients

Intravenous bevacizumab for HHT patients

age, HHT-type, symptoms, details on treatment indication and treatment protocol, efficacy of treatment, and adverse effects.

Collection process quality assessment

An interrater agreement test was performed on abstracts giving a kappa value of 0.69 corresponding to substantial agreement between the two selecting authors. The full text reading was not assessed by interrater agreement, as the few discrepancies were solved by discussion and inclusion of a third evaluator (JK).

Results of the quality assessment of the individual studies are shown in Table 5, this revealed that selection of patients were overall well performed, but that better ascertainment, causality and reporting of the treatment and treatment results, would have improved the studies.

Own case series

Twelve patients (8 females) with a median age of 67 years received treatment from 2013 to 2017 (Table 2). Eight patients had primarily epistaxis and four patients primarily GI-bleeding. Eleven out of twelve patients had increase in hemoglobin level. In 7 out of 11 patients a substantial reduction in transfusion need was registered. One patient with severe manifestations of HHT with large hepatic malformation, ascites, and severe right-sided heart failure did not survive for full follow-up. The following adverse events were registered: two patients described hair-loss, one patient experienced fatigue after infusion, and one patient stopped treatment due to facial pain.

Synthesis of results

The present study included eight case series (Table 3) with a total of 162 patients; 101 females, 61 males. The median age ranged from 54 to 68 years. Symptoms prior to systemic IV bevacizumab treatment varied between studies. Eight studies included information on the prevalence of epistaxis (n=148). Prevalence of GI bleeding (n=53) was addressed in six studies. In the study by Guilhem et al. (29) exact numbers was difficult to extract and was estimated using the authors conclusion that 74% had benefited from the treatment.

In total, 141 of 162 patients (87%) benefited from systemic IV bevacizumab treatment with reduced bleeding. Bleeding (epistaxis and/or GI bleeding) was the treatment indication in 106 patients (23,26-30), of whom 92 (87 %) had a positive effect of treatment with reduced bleeding, reduced transfusion needs, and/or increased levels of hemoglobin. Fifty-six patients from three studies (17,29,31) were primarily treated with systemic IV bevacizumab due to symptomatic hepatic involvement. Forty-nine of these (88%) also benefited from the treatment with reduced bleeding tendency.

In 32 case reports with 33 patients, 30 patients (91%) benefited from treatment. The cases included 15 females, 17 males, and 1 patient without details on gender (median age was 58 years ranging from five to 85). All patients were treated with systemic IV bevacizumab due to bleeding (epistaxis and/or GI bleeding). A number of adverse events were reported with hypertension, occurring in 17 patients as the most common. Five patients died during follow-up (Table 3 and Table 4).

Discussion

In the present study, we aimed to estimate the effect of systemic IV bevacizumab in the treatment of bleeding from the nasal mucosa and/or the GI tract due to telangiectasia in patients with HHT. We conducted a literature review and included seven published original dataset, 33 published cases, and our own unpublished dataset (21), in total 195 HHT patients. We found

<table>
<thead>
<tr>
<th>Study</th>
<th>Sex/Age</th>
<th>Symptoms</th>
<th>Treatment indication</th>
<th>Treatment protocol</th>
<th>Efficacy of treatment</th>
<th>Adverse effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ou et al. 2016</td>
<td>F 58</td>
<td>Epistaxis, GI bleeding, PAVM</td>
<td>Epistaxis + melena</td>
<td>5</td>
<td>24</td>
<td>DB, DT, IH</td>
</tr>
<tr>
<td>Parambil et al. 2018</td>
<td>M 61</td>
<td>Epistaxis</td>
<td>Epistaxis</td>
<td>5</td>
<td>6</td>
<td>NA None</td>
</tr>
<tr>
<td>Patrizia et al. 2010</td>
<td>M 50</td>
<td>Epistaxis, GI bleeding</td>
<td>Epistaxis</td>
<td>1</td>
<td>6</td>
<td>DB, DT, IH</td>
</tr>
<tr>
<td>Retornaz et al. 2009</td>
<td>F 65</td>
<td>Epistaxis, GI bleeding, HAVM</td>
<td>Epistaxis + melena</td>
<td>5</td>
<td>6</td>
<td>DB, DT, IH</td>
</tr>
<tr>
<td>Riviere et al. 2011</td>
<td>F 76</td>
<td>GI bleeding, PAVM</td>
<td>Melena</td>
<td>5</td>
<td>2</td>
<td>DB, DT, IH</td>
</tr>
<tr>
<td>Sehl et al. 2015</td>
<td>M 74</td>
<td>Epistaxis, GI bleeding</td>
<td>Melena</td>
<td>3.3</td>
<td>14</td>
<td>DB, DT, IH</td>
</tr>
<tr>
<td>Wee et al. 2014</td>
<td>M 55</td>
<td>Epistaxis, GI bleeding</td>
<td>Melena</td>
<td>2</td>
<td>4</td>
<td>DB, DT, IH</td>
</tr>
</tbody>
</table>

PAVM: pulmonary arteriovenous malformation; HAVM: hepatic arteriovenous malformation; DB: decreased bleeding; DT: decreased transfusion; IH: increased hemoglobin *No: Number of treatments are referred as correct as possible, total numbers or numbers per months/years.
that 88% of the patients benefitted from the treatment with systemic IV bevacizumab. Five patients out of 195 died in the follow-up period of the reported studies. None of the deaths were directly linked to bevacizumab treatment. In a newly
Intravenous bevacizumab for HHT patients

In this review we included all case series and case reports where intravenous bevacizumab has been used in the treatment of HHT patients, and where bleeding (epistaxis and/or GI-bleeding) before and after treatment has been recorded. In some publications the bleeding tendency was well described, including transfusion need and hemoglobin level. In other publications the information was scarce and only included the authors opinion of whether bevacizumab reduced bleeding or not. Thus, this uncertainty about outcome is a weakness of this study. However, we felt it important to include as many cases as possible, regarding this relatively rare treatment modality. The side effects from treatment with bevacizumab in cancer patients are well-described, and primarily include hypertension and bleeding (64). In this study we also found that hypertension was the most common side effect.

A further weakness in the evaluation of bevacizumab is the publication bias – studies with positive results of new treatments are more likely to be published than studies with negative results.

We thoroughly searched the literature for available publications on the effect of systemic bevacizumab in the treatment of bleeding from the nasal mucosa and/or the GI tract due to telangiectatic lesions in HHT patients. We have identified all relevant studies, but due to a limited number of original studies we found it necessary to include publications on single cases too. However, as single cases most often are highly selected this might increase the risks of publication bias. Results of the present study therefore need to be interpreted with caution. In this particular study there is also the risk that some cases may have registered twice, both as case reports from France (29,34,35,44) and included in the case series (27) from the same area.

From the present case series and case reports it is not possible to evaluate long-term effect of bevacizumab, but a majority of patients experience a clinical relevant reduction in bleeding, reducing need of transfusions, and elevating hemoglobin level. The use of systemic IV bevacizumab in the treatment of severe bleeding in HHT patients is still considered experimental and no uniform treatment protocol has been approved. However, most treatment protocols used in the present study where somewhat similar. The dose of bevacizumab administered was typically 5 mg/kg every second or third week in up to 12 weeks (seven of eight case series and in the majority of single case reports). In one of the reported studies (27) six patients received a small dose (0.125 mg/kg) of bevacizumab every fourth week for 24 weeks.

Conclusion
Based on the literature review and on our own case series, we believe that bevacizumab in a dose of 5 mg/kg with 3 weeks interval for 3-6 doses as induction therapy followed by maintenance therapy either at demand or at scheduled intervals is a treatment option for HHT patients with severe epistaxis and/or GI-bleeding. However, care should be taken using bevacizumab as long-term side effects have not been studied in this population. Furthermore the treatment is contraindicated in fertile women. A randomized controlled study is warranted to support the results in HHT patients – but may be difficult due to the rarity of the disease.

Acknowledgements
None applied.

Authorship contribution
AK and JK conceived the idea, TR performed the literature search and retrieved articles, AK, JK and ADF performed the screening of the titles read and discussed the articles. All authors participated in retrieving results from the articles. TR wrote the draft of the manuscript, all authors approved the manuscript.

Conflict of interest
Non declared.

References


Intravenous bevacizumab for HHT patients

Professor Anette Drøhse Kjeldsen, MD, PhD
Department of Otorhinolaryngology.
Odense University Hospital
5000 Odense C
Denmark
Tel: +45 2337 9822
E-mail: anette.kjeldsen@rsyd.dk